Inactive Instrument

Highlights Oncorus, Inc.

Equities

ONCR

US68236R1032

Highlights

Unlock all the news: Be the first to know and act before the market!

Oncorus, Inc. Enters into Lease Termination Agreement with IQHQ-4 Corporate, LLC	20/23/20	CI
Debt Limit Deal Approval, Jobs Data in Focus Amid Higher Exchange-Traded Funds, Equity Futures Pre-Bell Friday	02/23/02	MT
Oncorus, Inc. Contemplates Bankruptcy	01/23/01	CI
Oncorus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23/23/23	CI
North American Morning Briefing : Caution -2-	10/23/10	DJ
Oncorus, Daewoong Pharmaceutical to Develop Lipid Nanoparticle Formulations for mRNA Drug Candidate; Shares Surge	04/23/04	MT
Oncorus, Inc. and Daewoong Pharmaceutical Co., Ltd. Announce Research Collaboration for Discovery and Development of Novel Lipid Nanoparticle Formulations for mRNA Drug Candidates	04/23/04	CI
Oncorus, Inc. Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer	30/22/30	CI
Oncorus, Inc. Announces the Presentation of Preclinical Data for ONCR-719 in A Poster At the 2022 Society for Neuro-Oncology Annual Meeting	18/22/18	CI
Oncorus, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	02/22/02	CI
Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer	07/22/07	CI
Oncorus, Inc. Enters into Second Amendment (Lease Amendment) to its Existing Lease with BMR-HAMPSHIRE LLC	15/22/15	CI
Oncorus, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/22/04	CI
Oncorus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	04/22/04	CI
Oncorus, Inc. Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting	08/22/08	CI
Oncorus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	09/22/09	CI
Oncorus, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	09/22/09	CI
Oncorus, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	03/21/03	CI
Oncorus, Inc. to Present Initial Data from its Ongoing Phase 1 Clinical Trial of ONCR-177 At the Upcoming Society for Immunotherapy of Cancer’s 36th Annual Meeting	01/21/01	CI
ONCORUS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	05/21/05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oncorus, Inc.

Equities

ONCR

US68236R1032

Highlights

Filters